Health Sciences Research Center, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Hum Immunol. 2013 Sep;74(9):1061-8. doi: 10.1016/j.humimm.2013.05.009. Epub 2013 Jun 10.
Epigenetics has been gaining great attention as a therapeutic target in cancer. The cancer genome usually contains both hyper- and hypo-methylated genes to increase invasion, proliferation and metastasis. These cells not only operate their own growth, but also develop various strategies to escape from immune surveillance, and for this aim, regulatory T (Treg) cells support the cancer-mediated immune suppression. The fate of Treg cells is mainly controlled by DNA methylation within the promoter and intronic regions of Foxp3 gene. Foxp3 transcription factor is involved in the development, differentiation and function of Treg cells. COX-2 is also an epigenetically controlled gene in these processes. This enzyme and its product PGE2 plays essential roles in Treg functionality in cancer. Here, we discuss the effects of DNA methylation on cancer and nTreg cells. We also summarize the mechanisms related with COX-2/PGE2 and Foxp3 on inhibitory function of Treg cells in cancer.
表观遗传学作为癌症治疗靶点备受关注。肿瘤基因组通常包含超甲基化和低甲基化基因,以增加侵袭、增殖和转移。这些细胞不仅能自我增殖,还会发展出各种策略来逃避免疫监视,而调节性 T(Treg)细胞则支持癌症介导的免疫抑制。Treg 细胞的命运主要由 Foxp3 基因启动子和内含子区域内的 DNA 甲基化控制。Foxp3 转录因子参与 Treg 细胞的发育、分化和功能。COX-2 也是这些过程中受表观遗传控制的基因。该酶及其产物 PGE2 在癌症中 Treg 细胞功能中发挥重要作用。在这里,我们讨论了 DNA 甲基化对癌症和 nTreg 细胞的影响。我们还总结了与 COX-2/PGE2 和 Foxp3 相关的机制,这些机制与 Treg 细胞在癌症中的抑制功能有关。